#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Progressive multifocal leukoencephalopathy Isodicentric chromosome 15 syndrome Factor VIII deficiency Fusarium infection Acute graft versus host disease Restless legs syndrome Propionic acidaemia Hodgkin's disease recurrent Glomerulonephritis membranous Adrenocortical carcinoma Drug eruption KBG syndrome Cholangiosarcoma HER2 mutant non-small cell lung cancer Facioscapulohumeral muscular dystrophy More trials…

    Learn about Rare Diseases

    Activated PI3 kinase delta syndrome – Diagnostics Mucopolysaccharidosis III – Life with Disease Lysosomal storage disorder – Life with Disease Leiomyosarcoma metastatic – Treatment Glycogen storage disease type I – Basic Information Haemolytic uraemic syndrome Pulmonary sarcoidosis – Basic Information Paroxysmal nocturnal haemoglobinuria – Diagnostics Ewing’s sarcoma recurrent – Basic Information Wiskott-Aldrich syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sulodexide Ocrelizumab Gentamicin Sulfate ACETYLCARNITINE HYDROCHLORIDE Levothyroxine Temocillin Ly4100511 Clemastine Fumarate AAV9-CTNT-COBAG3 Empasiprubart Melphalan Flufenamide 68Ganota-Anti-Her2 Vhh1 Albumin Larotrectinib Sulfate GS-4321 Ecopipam Hydrochloride Danicopan Blood And Related Products RIVASTIGMINE Dermatophagoides Pteronyssinus More therapies…

    Learn about Your Condition

    Neurogenic bladder Benign renal neoplasm Biliary cancer metastatic Ureteric cancer Lower limb fracture Haemolytic uraemic syndrome Hand fracture Dermatitis IgA nephropathy Plasma cell myeloma Anxiety disorder Diabetes insipidus Ehlers-Danlos syndrome Endocarditis enterococcal Hernia repair More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

    Recruiting

    3 1
    Investigated Diseases:
    • Glomerulonephritis membranoproliferative
    Investigated Drugs:
    • Iptacopan Hydrochloride
    • Iptacopan
    Czechia Denmark France Germany Greece Italy +4

  • Study on Glioblastoma Recurrence: Comparing SonoCloud-9 with Carboplatin to Standard Treatments Lomustine or Temozolomide for Patients Undergoing Tumor Removal Surgery

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Glioblastoma
    Investigated Drugs:
    • Carboplatin
    • Perflutren
    • Temozolomide
    Austria Belgium Denmark France Germany Italy +3

  • Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Tamoxifen
    • Anastrozole
    • Letrozole
    Belgium Cyprus France Germany Greece Ireland +5

  • Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Telisotuzumab Vedotin
    • Docetaxel
    Austria Belgium Bulgaria Czechia Denmark France +10

  • Study on RVU120 and Venetoclax for Patients with Acute Myeloid Leukemia After Previous Treatment Failure

    Recruiting

    2 1 1 1 1
    Investigated Drugs:
    • 7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride
    • Venetoclax
    France Italy Poland Spain

  • Study Comparing Subcutaneous and Intravenous Nivolumab and Relatlimab for Patients with Untreated Metastatic or Unresectable Melanoma

    Recruiting

    3 1 1
    Investigated Diseases:
    • Metastatic malignant melanoma
    Investigated Drugs:
    • Nivolumab
    • Relatlimab
    Austria Belgium Czechia Finland France Germany +5
Previous Page
1 … 652 653 654 655 656 … 1,656
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!